Marker Therapeutics, Inc. (MRKR) |
|
1.4614 -0.299 (-16.97%)
|
03-22 12:11 |
|
Open: |
1.65 |
Pre. Close: |
1.76 |
|
High:
|
1.73 |
Low:
|
1.45 |
|
Volume:
|
28,678 |
Market Cap:
|
12(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 11:48:14 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 2.43  One year: 2.82 |
| Support: |
Support1: 1.54 Support2: 1.28 |
| Resistance: |
Resistance1: 2.08 Resistance2: 2.42 |
| Pivot: |
1.93 |
| Moving Average: |
MA(5): 1.78 MA(20): 1.98
MA(100): 2.9 MA(250): 3.26 |
| MACD: |
MACD(12,26): -0.3 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 17.4 %D(3): 21.1 |
| RSI: |
RSI(14): 25 |
| 52-week: |
High: 6.59 Low: 0.26 |
| Average Vol(K): |
3-Month: 42 (K) 10-Days: 35 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MRKR ] has closed below the lower bollinger band by 9.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ MRKR ] is to continue within current trading range. Bollinger Bands are 38.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.76 - 1.77 |
1.77 - 1.78 |
|
Low:
|
1.65 - 1.66 |
1.66 - 1.67 |
|
Close:
|
1.74 - 1.76 |
1.76 - 1.78 |
|
Company Description |
|
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas. |
Headline News |
Wed, 22 Mar 2023
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results - Yahoo Finance
Tue, 21 Mar 2023
JANONE INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers (form 8-K) - Marketscreener.com
Fri, 27 Jan 2023
Fate Therapeutics Inc (FATE) Stock Gains 4.94% This Week: Is It a Good Pick? - InvestorsObserver
Tue, 13 Dec 2022
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million - Yahoo Finance
Tue, 22 Nov 2022
Marker Therapeutics Announces FDA Clearance of IND for MT-601 ... - BioSpace
Thu, 10 Nov 2022
Marker Therapeutics Reports Q3 2022 Operating and Financial ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
9 (M) |
| Shares Float |
7 (M) |
|
% Held by Insiders
|
13.4 (%) |
|
% Held by Institutions
|
24.6 (%) |
|
Shares Short
|
49 (K) |
|
Shares Short P.Month
|
59 (K) |
Stock Financials |
|
EPS
|
-0.62 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.54 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-516.3 |
|
Return on Assets (ttm)
|
-39.7 |
|
Return on Equity (ttm)
|
-95.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-3.11 |
|
Sales Per Share
|
0.81 |
|
EBITDA (p.s.)
|
-3.91 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-26 (M) |
|
Levered Free Cash Flow
|
-16 (M) |
Stock Valuations |
|
PE Ratio
|
-2.58 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.9 |
|
Price to Sales
|
1.92 |
|
Price to Cash Flow
|
-0.53 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2016-09-15 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
